Volume | 968,336 |
|
|||||
News | - | ||||||
Day High | 42.775 | Low High |
|||||
Day Low | 41.97 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Ionis Pharmaceuticals Inc | IONS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
42.58 | 41.97 | 42.775 | 42.03 | 42.55 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,259 | 968,336 | $ 42.40 | $ 41,055,991 | - | 32.87 - 54.4446 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:49:46 | 50 | $ 42.28 | USD |
Ionis Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.12B | 145.75M | - | 787.65M | -366.29M | -2.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Ionis Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IONS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 43.97 | 44.64 | 41.68 | 42.80 | 1,090,273 | -1.94 | -4.41% |
1 Month | 44.40 | 47.66 | 41.68 | 44.55 | 1,311,275 | -2.37 | -5.34% |
3 Months | 51.63 | 54.4446 | 41.68 | 48.32 | 1,234,615 | -9.60 | -18.59% |
6 Months | 42.83 | 54.4446 | 41.57 | 47.79 | 1,183,927 | -0.80 | -1.87% |
1 Year | 35.71 | 54.4446 | 32.87 | 43.84 | 1,134,813 | 6.32 | 17.70% |
3 Years | 53.00 | 55.96 | 25.04 | 39.77 | 1,149,684 | -10.97 | -20.70% |
5 Years | 78.49 | 88.7075 | 25.04 | 47.10 | 1,091,799 | -36.46 | -46.45% |
Ionis Pharmaceuticals Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). |